These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26768118)

  • 1. TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors.
    Hantel C; Ozimek A; Lira R; Ragazzon B; Jäckel C; Frantsev R; Reincke M; Bertherat J; Mussack T; Beuschlein F
    Mol Cell Endocrinol; 2016 Mar; 423():87-95. PubMed ID: 26768118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
    Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
    Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
    Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
    Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression.
    Chen H; Hu L; Luo Z; Zhang J; Zhang C; Qiu B; Dong L; Tan Y; Ding J; Tang S; Shen F; Li Z; Wang H
    Mol Cancer; 2015 Nov; 14():186. PubMed ID: 26538215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
    Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
    Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma.
    Hantel C; Lewrick F; Reincke M; Süss R; Beuschlein F
    J Endocrinol; 2012 May; 213(2):155-61. PubMed ID: 22407999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
    Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
    Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
    Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulated A20 promotes proliferation, regulates cell cycle progression and induces chemotherapy resistance of acute lymphoblastic leukemia cells.
    Chen S; Xing H; Li S; Yu J; Li H; Liu S; Tian Z; Tang K; Rao Q; Wang M; Wang J
    Leuk Res; 2015 Sep; 39(9):976-83. PubMed ID: 26159495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.
    Milanović D; Braun F; Weber W; Grosu AL; Behe M; Niedermann G
    BMC Cancer; 2012 Jun; 12():242. PubMed ID: 22695475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma.
    Kuai R; Subramanian C; White PT; Timmermann BN; Moon JJ; Cohen MS; Schwendeman A
    Int J Nanomedicine; 2017; 12():6581-6594. PubMed ID: 28919755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cAMP-dependent protein kinase activation inhibits proliferation and enhances apoptotic effect of tumor necrosis factor-alpha in NCI-H295R adrenocortical cells.
    Liu J; Li XD; Ora A; Heikkilä P; Vaheri A; Voutilainen R
    J Mol Endocrinol; 2004 Oct; 33(2):511-22. PubMed ID: 15525605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
    Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
    Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A20 inhibits human salivary adenoid cystic carcinoma cells invasion via blocking nuclear factor-kappaB activation.
    Zhang B; Guan CC; Chen WT; Zhang P; Yan M; Shi JH; Qin CL; Yang Q
    Chin Med J (Engl); 2007 Oct; 120(20):1830-5. PubMed ID: 18028781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
    Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
    Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
    Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
    Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study.
    Fiorentini C; Fragni M; Perego P; Vezzoli S; Bonini SA; Tortoreto M; Galli D; Claps M; Tiberio GA; Terzolo M; Missale C; Memo M; Procopio G; Zaffaroni N; Berruti A; Sigala S
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4594-4602. PubMed ID: 27626976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
    Head M; Jameson MB
    Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. n-3 polyunsaturated fatty acids abrogate mTORC1/2 signaling and inhibit adrenocortical carcinoma growth in vitro and in vivo.
    Liu J; Xu M; Zhao Y; Ao C; Wu Y; Chen Z; Wang B; Bai X; Li M; Hu W
    Oncol Rep; 2016 Jun; 35(6):3514-22. PubMed ID: 27035283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.